Surprisingly, Hamid et al. found a positive correlation between clinical efficacy of CTLA-4 blockade and a high baseline expression of either the Treg cell-associated transcription factor FoxP3 or the immunosuppressive molecule indoleamine 2,3-dioxygenase (IDO) in melanoma patients (29). Here, CTLA4 is linked to melanoma.